Skip to content

Stephen Berenson

Managing Partner

Stephen Berenson is a managing partner at Flagship Pioneering and a member of the company's Resource Allocation and Management Committees. He is also responsible for Flagship's Capital Formation and Business Development functions. Stephen is chairman of the boards of Cellarity and Seres Therapeutics (NASDAQ: MCRB) and is on the board of directors at Moderna (NASDAQ: MRNA).

Stephen joined Flagship in June of 2017 after a 33-year career as an investment banker at J.P. Morgan. During that time, he worked across all major geographies, product areas and industry groups, and helped build the bank’s M&A, equities and technology investment banking businesses. During his last twelve years at J.P. Morgan, Stephen was vice chairman of investment banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. During Stephen’s leadership of the Board Initiative, more than 1,000 independent directors of public companies attended at least one of J.P. Morgan’s board events to discuss, debate and share best practices on the key issues they faced in the fulfillment of their duties.

Stephen also made important contributions to J.P. Morgan’s culture through his deep support of recruiting, training and development, and mentoring, and he helped to build and maintain a robust control environment through his participation on the firm’s Equity Underwriting and Reputational Risk Committees.

Stephen graduated from MIT in 1982 with an S.B. in mathematics. He is a member of the Visiting Committee for MIT’s Department of Mathematics, a member of the board of trustees of Jacob’s Pillow, and a former member of the board of trustees of the Mahaiwe Performing Arts Center in Great Barrington, Massachusetts. He is also a former member of the boards of directors of Flagship-founded companies CiBO Technologies and Repertoire Immune Medicines.